Epstein–Barr Virus (HHV-4) Infections Drug pipeline Report 2020- Current Status, Phase, Mechanism, Route of Administration, Companies, and Clinical Trials of Pre-clinical and Clinical Drugs

October 2019 | 90 pages | ID: E56D459D2AD3EN
VPAResearch

Abstracts

Epstein–Barr Virus (HHV-4) Infections Drug pipeline report- 2020 is an annual R&D review of Epstein–Barr Virus (HHV-4) Infections pipeline candidates. The report presents the current status of all major Epstein–Barr Virus (HHV-4) Infections therapeutic compounds. Detailed insights into Epstein–Barr Virus (HHV-4) Infections pipeline development, current status, companies, drug profiles and Epstein–Barr Virus (HHV-4) Infections preclinical and clinical trials are included.

2020 Epstein–Barr Virus (HHV-4) Infections Pipeline Market Insights
Epstein–Barr Virus (HHV-4) Infections disease overview, 2020 pipeline review, insights into leading companies, dominant mechanism of action, majority of administration route of Epstein–Barr Virus (HHV-4) Infections therapies, pipeline by phase and others are included.

Epstein–Barr Virus (HHV-4) Infections pipeline Drug profiles-
Active and inactive drug profiles covering information including drug name/synonym, sponsor/collaborators/Developer/originator, drug mechanism, route of administration, orphan drug status, NME, phase, development status, and others are included.

Epstein–Barr Virus (HHV-4) Infections Therapeutic Drug candidates
Both active and inactive Epstein–Barr Virus (HHV-4) Infections pipeline drug candidates are included in the report

Epstein–Barr Virus (HHV-4) Infections Clinical Trials and preclinical Studies
Epstein–Barr Virus (HHV-4) Infections In-vitro and In-vivo studies, discovery stage and pre-clinical stage trial details, Clinical trial titles, duration, location, phase, sponsors, and other details are provided.

Epstein–Barr Virus (HHV-4) Infections pipeline market developments
Epstein–Barr Virus (HHV-4) Infections Pipeline market news and deals including mergers, acquisitions, approvals, collaborations, trial initiations, results, investments, licensing opportunities and others are provided.

Epstein–Barr Virus (HHV-4) Infections pipeline companies in active development
The report analyzes Epstein–Barr Virus (HHV-4) Infections pipeline of the below companies-

Advenchen Laboratories LLC, Atara Biotherapeutics Inc, Biotron Ltd, bluebird bio Inc, Boryung ViGenCell Inc , Bristol-Myers Squibb Co, Cell Medica Ltd, Eutilex Co Ltd, Genocea Biosciences Inc, Lion TCR Pte Ltd, Omeros Corp, Sapvax, TC BioPharm Ltd, Tessa Therapeutics Pte Ltd, Viracta Therapeutics Inc, ViraCyte LLC, Vironika LLC, ViroStatics srl

Report Coverage

What to look out for in 2020
Drugs moving from early stage to mid-to-late stages and drugs to look after in 2020 are included

Pipeline Snapshot
Pipeline candidate count - Drug by phase, mechanism of action, route of administration, designation and others

Companies
18 Companies investing in Epstein–Barr Virus (HHV-4) Infections pipeline from discovery stage to pre-registration phase are included

Drug profiles
Over 10 details of each Epstein–Barr Virus (HHV-4) Infections pipeline candidate are included

Company Profiles
Business overview and contact details of all companies operating in the industry are provided

Market Developments
News, Developments and other recent industry developments are included

Contents

1. EPSTEIN–BARR VIRUS (HHV-4) INFECTIONS PIPELINE MARKET INSIGHTS, 2020

1.1 Epstein–Barr Virus (HHV-4) Infections Disease Overview
1.2 Epstein–Barr Virus (HHV-4) Infections Drug Pipeline Snapshot, 2020
  1.2.1 Epstein–Barr Virus (HHV-4) Infections Pipeline Drugs by Phase
  1.2.2 Epstein–Barr Virus (HHV-4) Infections Pipeline Drugs by Company
  1.2.3 Epstein–Barr Virus (HHV-4) Infections Pipeline Drugs by Mechanism of Action
  1.2.4 Epstein–Barr Virus (HHV-4) Infections Pipeline Drugs by Route of Administration

2. EPSTEIN–BARR VIRUS (HHV-4) INFECTIONS COMPANY WISE PIPELINE DETAILS

Advenchen Laboratories LLC Epstein–Barr Virus (HHV-4) Infections Pipeline Drugs
  Company Profile
  Drug Candidate Details
Atara Biotherapeutics Inc Epstein–Barr Virus (HHV-4) Infections Pipeline Drugs
  Company Profile
  Drug Candidate Details
Biotron Ltd Epstein–Barr Virus (HHV-4) Infections Pipeline Drugs
  Company Profile
  Drug Candidate Details
bluebird bio Inc Epstein–Barr Virus (HHV-4) Infections Pipeline Drugs
  Company Profile
  Drug Candidate Details
Boryung ViGenCell Inc Epstein–Barr Virus (HHV-4) Infections Pipeline Drugs
  Company Profile
  Drug Candidate Details
Bristol-Myers Squibb Co Epstein–Barr Virus (HHV-4) Infections Pipeline Drugs
  Company Profile
  Drug Candidate Details
Cell Medica Ltd Epstein–Barr Virus (HHV-4) Infections Pipeline Drugs
  Company Profile
  Drug Candidate Details
Eutilex Co Ltd Epstein–Barr Virus (HHV-4) Infections Pipeline Drugs
  Company Profile
  Drug Candidate Details
Genocea Biosciences Inc Epstein–Barr Virus (HHV-4) Infections Pipeline Drugs
  Company Profile
  Drug Candidate Details
Lion TCR Pte Ltd Epstein–Barr Virus (HHV-4) Infections Pipeline Drugs
  Company Profile
  Drug Candidate Details
Omeros Corp Epstein–Barr Virus (HHV-4) Infections Pipeline Drugs
  Company Profile
  Drug Candidate Details
Sapvax Epstein–Barr Virus (HHV-4) Infections Pipeline Drugs
  Company Profile
  Drug Candidate Details
TC BioPharm Ltd Epstein–Barr Virus (HHV-4) Infections Pipeline Drugs
  Company Profile
  Drug Candidate Details
Tessa Therapeutics Pte Ltd Epstein–Barr Virus (HHV-4) Infections Pipeline Drugs
  Company Profile
  Drug Candidate Details
Viracta Therapeutics Inc Epstein–Barr Virus (HHV-4) Infections Pipeline Drugs
  Company Profile
  Drug Candidate Details
ViraCyte LLC Epstein–Barr Virus (HHV-4) Infections Pipeline Drugs
  Company Profile
  Drug Candidate Details
Vironika LLC Epstein–Barr Virus (HHV-4) Infections Pipeline Drugs
  Company Profile
  Drug Candidate Details
ViroStatics srl Epstein–Barr Virus (HHV-4) Infections Pipeline Drugs
  Company Profile
  Drug Candidate Details

3. EPSTEIN–BARR VIRUS (HHV-4) INFECTIONS DRUG PIPELINE PROFILES

3.1 Discovery and Preclinical Drug Profiles
3.2 Phase 1 Drug Profiles
3.3 Phase 2 Drug Profiles
3.4 Phase 3 Drug Profiles

4. EPSTEIN–BARR VIRUS (HHV-4) INFECTIONS PIPELINE NEWS AND DEVELOPMENTS

5. APPENDIX

5.1 Primary and Secondary Research Methodology
5.2 Publisher Expertize
5.3 Contacts